药康生物(688046) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥140,304,915.96, representing a year-on-year increase of 20.82%[5] - The net profit attributable to shareholders was ¥31,050,205.03, with a slight increase of 2.39% compared to the same period last year[5] - Total revenue for Q1 2023 reached CNY 140,304,915.96, an increase of 20.8% compared to CNY 116,124,141.67 in Q1 2022[21] - The company reported a net profit of CNY 32,512,084.14 for Q1 2023, compared to CNY 34,978,494.83 in Q1 2022, indicating a decline of 7.1%[22] - The total comprehensive income for Q1 2023 was CNY 30,874,134.84, slightly up from CNY 30,284,840.56 in Q1 2022[23] Research and Development - Research and development (R&D) expenses totaled ¥24,232,493.78, which is an increase of 36.45% year-on-year, accounting for 17.27% of operating revenue[6] - The company is actively pursuing multiple large-scale R&D projects, including "spotted mice" and "sterile mice," contributing to increased R&D costs[10] - Research and development expenses increased to CNY 24,232,493.78 in Q1 2023, up 36.4% from CNY 17,759,796.98 in Q1 2022[22] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥14,154,229.37, indicating a significant cash outflow during the quarter[5] - Operating cash inflow for Q1 2023 was CNY 117,224,294.83, up from CNY 90,993,276.97 in Q1 2022, representing a growth of 29.0%[24] - The net cash flow from operating activities was -CNY 14,154,229.37, an improvement from -CNY 26,057,726.69 in the same period last year[24] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 447,070,730.89, compared to CNY 183,906,106.56 at the end of Q1 2022, indicating a significant increase[25] - The company reported cash inflow from investment activities of CNY 434,308,686.92, a substantial rise from CNY 151,747,133.95 in Q1 2022[25] - The net cash flow from investment activities was CNY 20,681,732.96, recovering from -CNY 61,942,557.82 in the previous year[25] - The company generated CNY 21,000,000.00 from financing activities in Q1 2023, compared to CNY 993,665.95 in Q1 2022[25] - The net cash flow from financing activities was CNY 19,306,733.72, a recovery from -CNY 21,547,704.06 in the same quarter last year[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,323,892,234.73, reflecting a 3.11% increase from the end of the previous year[6] - Total assets as of March 31, 2023, amounted to CNY 2,323,892,234.73, an increase of 3.1% from CNY 2,253,694,612.84 at the end of 2022[18] - Total liabilities as of March 31, 2023, were CNY 313,308,868.24, up 13.5% from CNY 276,002,396.33 at the end of 2022[18] - The company’s total equity as of March 31, 2023, was CNY 2,010,583,366.49, an increase of 1.7% from CNY 1,977,692,216.51 at the end of 2022[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,281[12] - The largest shareholder, Nanjing Laoyan Venture Capital Partnership, holds 201,817,185 shares, representing 49.22% of total shares[13] - Qingdao Guoyao Dacreat Investment Partnership holds 34,745,078 shares, accounting for 8.47% of total shares[13] - The company has a total of 6,122,240 unrestricted circulating shares held by the National Social Security Fund[14] - The top ten shareholders include various investment funds, with significant holdings such as 1,122,016 shares by Wu Qing[14] Operational Conditions - The company has not reported any significant changes in operational conditions during the reporting period[15] - The weighted average return on equity decreased to 1.56%, down by 2.23 percentage points from the previous year[6] - Basic and diluted earnings per share remained stable at CNY 0.08 for both Q1 2023 and Q1 2022[23] - Inventory as of March 31, 2023, was CNY 49,894,276.38, slightly up from CNY 49,470,606.40 at the end of 2022[17] - Total operating costs for Q1 2023 were CNY 109,276,292.77, up 30.1% from CNY 83,981,505.89 in Q1 2022[22] - Operating profit for Q1 2023 was CNY 32,512,083.12, a decrease of 7.1% from CNY 34,979,286.77 in Q1 2022[22]